Name (Synonyms) | Correlation | |
---|---|---|
drug1025 | Estradiol patch Wiki | 0.71 |
drug1033 | Examine the impact of COVID-19 during pregnancy Wiki | 0.71 |
drug707 | ColdZyme® mouth spray Wiki | 0.71 |
drug2122 | Placebo Wiki | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.25 |
D008173 | Lung Diseases, Obstructive NIH | 0.24 |
D012141 | Respiratory Tract Infections NIH | 0.14 |
D003141 | Communicable Diseases NIH | 0.06 |
D007239 | Infection NIH | 0.04 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0006510 | Chronic pulmonary obstruction HPO | 0.25 |
HP:0006536 | Pulmonary obstruction HPO | 0.24 |
HP:0011947 | Respiratory tract infection HPO | 0.14 |
There are 2 clinical trials
This study evaluates the performance of ColdZyme® mouth spray on prevention and alleviation of induced rhinovirus upper respiratory tract infection in healthy volunteers. Half of participants will receive ColdZyme® mouth spray while the other half will receive placebo.
Description: Reduction in viral load in the URT(Upper Respiratory Tract), after challenge with rhinovirus, in relation to placebo
Measure: Reduction in viral load in the URT Time: 7 daysDescription: Reduction of number of days having a total symptom severity score of 6 or higher using a 5-graded Jackson scale, in relation to placebo.
Measure: Prevention of symptomatic URTI (Upper Respiratory Tract Infection) Time: 11 daysDescription: Asymptomatic URTI will be assessed by quantification of viral load at peak day (day with highest viral load measured by oropharyngeal swab).
Measure: Prevention of asymptomatic URTI. Time: 11 daysDescription: The number of days with cold is defined as the sum of all days with a total score of ≥ 6 according to the modified method of Jackson.
Measure: Fewer days with symptomatic URTI Time: 11 daysDescription: The number of days with asymptomatic URTI is defined as the sum of all days with a viral load significantly different from the baseline.
Measure: Fewer days with asymptomatic URTI. Time: 11 daysDescription: Nasal samples will be analysed for the quantity of IL-6 (Interleukin 6), IL-8 and IFNα (Interferon alpha).
Measure: Lower level of proinflammatory proteins Time: 11 daysAn open access study that will define and collect digital measures of coughing in multiple populations and public spaces using various means of audio data collection.
Description: Size of collected audio dataset measured as number of collected cough sounds, targeting ≥10,000 identified coughs.
Measure: Dataset size Time: 14 daysDescription: Identification of cough sounds by the existing mathematical model with ≥ 99% specificity and ≥ 60% sensitivity
Measure: Cough sound identification Time: 14 daysDescription: Increase in the sensitivity of the mathematical model to cough sounds to ≥ 70% while retaining the specificity of ≥ 99%
Measure: Improvement of the existing model Time: 14 daysDescription: Determination of the level of acceptance and satisfaction of the solution by patients by means of a Standard Usability Questionnaire to provide feedback. The score ranges from 10 to 50, higher score indicating a better usability.
Measure: Evaluate the usability of the application Time: 14 days